Skip to main content
Equibles

MARSHALL WACE, LLP

Position in TBPH — Theravance Biopharma, Inc.

CIK 1318757 LONDON, X0
Back to TBPH Full portfolio

Position in TBPH

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$3,208,716
+$629,770 QoQ
Shares Held
188,748
+18.8% QoQ
Ownership
0.364%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#28
of 179 holders
Holding Since
Jun 2020
13 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in TBPH Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. TBPH ranks #120 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 543,897 $270,169,956
2 INCY
Incyte Corp
 1,310,154 $148,519,056
3 RPRX
Royalty Pharma plc
 2,450,669 $137,409,009
4 SYRE
Spyre Therapeutics, Inc.
 991,693 $88,042,503
5 ALNY
Alnylam Pharmaceuticals, Inc.
 259,799 $78,207,292
6 TVTX
Travere Therapeutics, Inc.
 1,333,207 $75,739,488
7 MANE
Veradermics, Inc
 585,560 $71,988,746
8 DFTX
Definium Therapeutics, Inc.
 1,298,946 $61,102,419

All Filings in TBPH

Export CSV
13 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $3,208,716 188,748
2026-03-31 $2,578,946 158,900
2025-12-31 $7,832,547 418,629
2025-09-30 $5,221,704 357,651
2025-06-30 $1,111,581 100,778
2025-03-31 $133,155 14,911
2024-12-31 $621,690 66,067
2024-09-30 $1,209,483 150,060
2024-06-30 $2,522,791 297,499
2024-03-31 $1,453,794 162,073
2023-09-30 $176,052 20,400
2023-06-30 $619,054 59,812
2020-06-30 $314,640 14,990